FreeGulliver LLC Cuts Position in Pfizer Inc. (NYSE:PFE)

FreeGulliver LLC decreased its holdings in Pfizer Inc. (NYSE:PFE) by 5.1% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 15,522 shares of the biopharmaceutical company’s stock after selling 840 shares during the period. FreeGulliver LLC’s holdings in Pfizer were worth $412,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. VSM Wealth Advisory LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $72,000. Compass Ion Advisors LLC raised its stake in shares of Pfizer by 55.6% during the fourth quarter. Compass Ion Advisors LLC now owns 24,295 shares of the biopharmaceutical company’s stock valued at $645,000 after purchasing an additional 8,677 shares during the period. Enhancing Capital LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $1,104,000. Xponance Inc. raised its stake in shares of Pfizer by 4.2% during the fourth quarter. Xponance Inc. now owns 851,248 shares of the biopharmaceutical company’s stock valued at $22,584,000 after purchasing an additional 34,344 shares during the period. Finally, Generali Asset Management SPA SGR purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $11,538,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Truist Financial dropped their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Bank of America restated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Citigroup dropped their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Performance

Pfizer stock opened at $26.31 on Wednesday. The company has a market cap of $149.09 billion, a PE ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a fifty day moving average price of $26.21 and a two-hundred day moving average price of $27.09. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the previous year, the company posted $0.10 earnings per share. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.